Physician profile
Brian E Couse
NPI 1013904812
$1,557.32
in general payments reported to CMS, 2019-2025
20 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $542 · 2021: $229 · 2023: $23.46 · 2024: $20.08 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $347.76 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $265.92 | 2019-2021 | |
| Allergan, INC. | $139.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $105.18 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $93.86 | 2019-2020 | |
| Abbvie INC. | $91.47 | 2019-2025 | Dalvance |
| Astellas Pharma US INC | $87.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.90 | 2019-2021 | |
| Amgen INC. | $55.40 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $48.26 | 2019 | |
| Eisai INC. | $45.87 | 2021 | |
| Glaxosmithkline, LLC. | $39.82 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $24.86 | 2025 | Rexulti |
| Lilly USA, LLC | $24.46 | 2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $23.60 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $20.08 | 2024 | |
| Axsome Therapeutics, INC. | $18.83 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.64 | 2021 | |
| Amarin Pharma, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Couse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.